REFERENCES
- Antoni S, Ferlay J, Soerjomataram I, et
al. Bladder
cancer incidence and mortality: A global overview and recent trends.Eur Urol. 2017;71: 96.
- Miyazaki J, Nishiyama
H. Epidemiology of
urothelial carcinoma. Int J Urol. 2017;24:730-34.
- Baykan O, Akgul M, Uren
N, et al. The
Relationship Between Urothelial Type Bladder Cancer, Plasma
25-Hydroxyvitamin D Levels, and Vitamin D Receptor ApaI BsmI FokI, and
TaqI Polymorphisms. Clin
Lab .2019,65.10.7754/Clin.Lab.2018.180339.
- Cumberbatch MGK, Jubber I, Black PC, et
al. Epidemiology
of Bladder Cancer: A Systematic Review and Contemporary Update of Risk
Factors in. 2018. Eur Urol. 2018;74: 784-95.
- TNM
classification of malignant tumors. UICC International Union
Against Cancer. 8th edn. Brierley JD, Gospodarowicz M, Wittekind C
(Eds. 2017, Wiley-Blackwell)
- Mostafid AH. Time to
re‐evaluate and refine re‐transurethral resection in bladder cancer?.BJU international . 2016;118:9-10.
- Adiyat KT, Katkoori D, Soloway CT, De Los Santos R, Manoharan M,
Soloway
MS. “Complete
transurethral resection of bladder tumor” are the guidelines being
followed? Urology. 2010;75:365-67.
- Witjes JA, Moonen PMJ, Van Der Heijden AG.
Review
pathology in a diagnostic bladder cancer trial: effect of patient risk
category. Urology. 2006; 67:751-55.
- Babjuk M, Burger M, Compérat E, et
al. EAU
guidelines on non-muscle-invasive (Ta, T1 and CIS) bladder cancer, in
EAU guidelines. 2020, European Association of Urology guidelines
office Arnhem, the Netherlands.
- Baltacı S, Bozlu M, Yıldırım A, et
al. Significance of the
interval between first and second transurethral resection on
recurrence and progression rates in patients with high-risk
non-muscle-invasive bladder cancer treated with maintenance
intravesical Bacillus Calmette-Guérin. BJU Int. 116(5),
721-726.
- Fritsche HM, Burger M, Svatek RS, et
al. Characteristics
and out- comes of patients with clinical T1 grade 3 urothelial
carcinoma treated with radical cystectomy: results from an
international cohort. Eur Urol. 2010;57:300
- Herr HW, Donat
SM. A
re-staging transurethral resection predicts early progression of
superficial bladder cancer. BJU Int. 2006;97: 1194:8.
- Naselli A, Hurle R, Paparella S, et
al. Role of
Restaging Transurethral Resection for T1 Non-muscle invasive Bladder
Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus.2018;4:558-67.
- Cumberbatch MGK, Foerster B, Catto JWF, et
al. Repeat
Transurethral Resection in Non-muscle-invasive Bladder Cancer: A
Systematic Review. Eur Urol. 2018;73: 925-33.
- Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larré
S. Recurrence,
progression and cancer-specific mortality according to stage at re-TUR
in T1G3 bladder cancer patients treated with BCG: not as bad as
previously thought. World journal of urology. 2018;36:1621-27.
- Gaya JM, Palou J, Cosentino M, Patiño D, Rodríguez-Faba O,
Villavicencio
H. A second
transurethral resection could be not necessary in all high grade
non-muscle-invasive bladder tumours. Actas Urológicas Españolas
(English). 2012:539-44.
- Ho HC, Hughes T, Bozlu M, Kadıoğlu A, Somani
BK. What do
urologists need to know: Diagnosis, treatment, and follow-up during
COVID-19 pandemic. Turkish Journal of Urology. 2020;46:169.
- Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu
F: Impact of
routine second transurethral resection on the long-term outcome of
patients with newly diagnosed pT1 urothelial carcinoma with respect to
recurrence, progression rate, and disease-specific survival: a
prospective randomised clinical trial. Eur Urol.2010;58:185-90.
- Sfakianos JP, Kim PH, Hakimi AA, Herr
HW. The effect of
restaging transurethral resection on recurrence and progression rates
in patients with nonmuscle invasive bladder cancer treated with
intravesical bacillus Calmette-Guerin. J Urol. 2014;191:
341-5.
- Gontero P, Sylvester R, Pisano F, et
al. The impact of
re‐transurethral resection on clinical outcomes in a large multicentre
cohort of patients with T1 high‐grade/Grade 3 bladder cancer treated
with bacille Calmette-Guérin. BJU international.2016;118:44-52.
- Calò B, Chirico M, Fortunato F, et
al. Is repeat
transurethral resection always needed in high-grade T1 bladder
cancer?. Frontiers in Oncology. 2019;9.
- Bishr M, Lattouf JB, Latour
M, Saad F. Tumour stage on
re-staging transurethral resection predicts recurrence and
progression-free survival of patients with high-risk non-muscle
invasive bladder cancer. Can Urol Assoc J. 2014;8:306-10.
- Witjes J, Bruins HM, Cathomas R, et
al. EAU
Guidelines on Muscle-invasive and Metastatic Bladder Cancer, in EAU
Guidelines. 2020, European Association of Urology Guidelines Office
Arnhem, The Netherlands.